# Effect of Neoadjuvant Chemotherapy on Angiogenesis and Cell Proliferation of Breast Cancer Evaluated by Dynamic Enhanced Magnetic Resonance Imaging.

> **Reliability concern:** This paper was retracted on 2023-06-21. See notice: 10.1155/2023/9784125.

- **DOI:** [10.1155/2022/3156093](https://doi.org/10.1155/2022/3156093)
- **Rating:** Limited (2.0 out of 5)
- **Verdict:** A clinically relevant breast cancer imaging study rendered uninterpretable by an unidentifiable comparator drug, internal reporting inconsistencies, and undefined biomarkers.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-06-01
- **Evaluation page:** https://www.nabu.science/paper/10.1155%2F2022%2F3156093

## Strengths

- **Clinically relevant research question addressed** The study targets a recognised unmet need: non-invasive evaluation of neoadjuvant chemotherapy response in breast cancer using DCE-MRI quantitative parameters, an active area of clinical and imaging research.
  - Dimension: contribution
  - Location: Introduction §1
- **Multimodal assessment combining imaging and biomarkers** The study examines both DCE-MRI quantitative parameters (Ktrans, Kep, Ve, ADC) and protein expression markers (cell proliferation and angiogenesis), providing biological plausibility for the observed imaging differences.
  - Dimension: methodological rigour
  - Location: Results §3.1–3.4
- **Appropriate basic statistical methodology** The statistical approach includes Shapiro-Wilk normality testing with appropriate selection of parametric or non-parametric tests based on data distribution, demonstrating a basic level of analytical care.
  - Dimension: methodological rigour
  - Location: Methods §2.4

## Limitations

- **Unidentifiable comparator drug renders comparison uninterpretable** The routine chemotherapy group received 'grace 7.5 mg/(m2·d),' which is not a recognised drug name and appears to be a translation artefact. The actual comparator treatment cannot be determined, making all between-group comparisons uninterpretable.
  - Dimension: methodological rigour
  - Location: Methods §2.3.1
- **Material internal inconsistencies between abstract and results** The abstract reports 'Ktranspre' had no significant difference while Results §3.1 reports 'Ktranspost' was significantly higher — an apparent swap between pre- and post-treatment parameters. The Discussion contains temporal framing contradictions regarding when Ktrans and Kep changes occurred. These inconsistencies undermine confidence in the reported findings.
  - Dimension: reporting
  - Location: Abstract; Results §3.1; Discussion §4
- **Contradictory data availability and absent research transparency** The Data Availability Statement claims 'No data were used to support this study,' which is factually impossible for a study reporting quantitative data from 80 patients. Ethics approval lacks an identifier, no conflict of interest disclosure is provided, and the randomised allocation to chemotherapy regimens lacks clinical trial registration.
  - Dimension: methodological rigour
  - Location: Data Availability Statement; Methods §2.1

## Reliability checks

Concerns (4 of 4 checks).

- **Internal coherence:** Concern. The paper contains material internal inconsistencies between the abstract and results sections regarding which DCE-MRI parameters showed significant differences (Ktranspre vs Ktranspost). The comparator chemotherapy drug is unidentifiable ('grace,' §2.3.1), multiple biomarkers are undefined (ALEXI, Aurora, Nek2), the Vp parameter defined in the methods never appears in results, and numerous machine-translation artefacts impede interpretation throughout.
- **Research conduct:** Concern. The Data Availability Statement ('No data were used to support this study') is factually impossible for a study analyzing 80 patients' MRI scans, blood parameters, and tissue samples. Ethics approval is declared without an IRB identifier or committee name. No conflict of interest statement, protocol registration, or reporting standard is provided. The described 'random number table' allocation to chemotherapy regimens constitutes an interventional study without clinical trial registration.
- **Reference integrity:** Clean. All 34 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Concern
- **Summary:** This paper was retracted on 2023-06-21. See notice: 10.1155/2023/9784125.
- **Last checked:** 2026-10-17
